Immunology superstar Dupixent, which first brought Regeneron and Sanofi together in 2007, has entered its megablockbuster era ...

According to the lawsuit, Sanofi has failed to provide partner Regeneron adequate information regarding the sales of Dupixent ...

The arrangement is somewhat complex, but Regeneron notes in its latest investor presentation that reimbursement balance due to Sanofi - ~$700m in 2024 -will be repaid by 2026, at which point ...

We note that Sanofi records global net product sales of Dupixent and Kevzara, while Regeneron records its share of profits/losses in connection with the global sales of both drugs. Dupixent’s ...

The U.S. Food and Drug Administration approved Merilog as biosimilar to Novolog for the improvement of glycemic control in adults and pediatric ...

More than 1,000,000 patients are currently being treated with Dupixent globally. Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement. To date, dupilumab ...

Regeneron posted Q4 adjusted EPS of $12.07 ... while Libtayo sales surged 50% to $367M. Sanofi collaboration revenue also increased. Get real-time earnings alerts before the market moves and ...

The company's collaboration revenue derived from partnerships with Sanofi and Bayer rose by 17% to nearly $1.61 billion. Regeneron also proffered selected guidance for the entirety of 2025.